MNOV Stock Medicinova (MNOV, $1.27) Moving Average Convergence Divergence (MACD) Histogram turned negative on July 1, 2025

GET DAILY SIGNALS

Get AI intraday signals

MNOV - Medicinova

MACD signal

View

Odds of DOWN Trend

Price: $1.27

Daily change: -$0.04 (-3.05%)

Daily volume: 11.8K

Capitalization: $62.3M

Industry: Biotechnology

MNOV sees MACD Histogram crosses below signal line

MNOV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 01, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

MNOV moved below its 50-day moving average on June 05, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNOV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MNOV entered a downward trend on June 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MNOV's RSI Oscillator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on MNOV as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MNOV advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .

MNOV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.248) is normal, around the industry mean (16.522). P/E Ratio (0.000) is within average values for comparable stocks, (58.479). MNOV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.315). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (98.039) is also within normal values, averaging (261.553).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MNOV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.